Inhibition of calcium-sensing receptor by its antagonist promotes gastrointestinal motility in a Parkinson’s disease mouse model

• Published in: Biomedicine & pharmacotherapy Vol. 174; p. 116518
• Main Authors: Li, Yu-Hang, Jiang, Zhong-Xin, Xu, Qian, Jin, Ting-Ting, Huang, Jin-Fang, Luan, Xiao, Li, Chong, Chen, Xin-Yi, Wong, Ka-Hing, Dong, Xiao-Li, Sun, Xiang-Rong
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.05.2024; Elsevier
• Subjects: Animals; Calcium-sensing receptor; Disease Models, Animal; Gastric Emptying - drug effects; Gastrointestinal motility; Gastrointestinal Motility - drug effects; Male; Mice; Mice, Inbred C57BL; Naphthalenes; NPS-2143; Parkinson Disease - drug therapy; Parkinson Disease - metabolism; Parkinson Disease - physiopathology; Parkinson’s disease; Receptors, Calcium-Sensing - antagonists & inhibitors; Receptors, Calcium-Sensing - metabolism; NNOS; NO; CaSR; IRN; ANS; CHAT; LMMP; CCh; CNS; Gastrointestinal motility; ENS; NTS; 5-HT4; TTX; IBS; Calcium-sensing receptor; IF; PBS; GI; AD; GLP-1; Ach; ICC; SNpc; CCK; DMV; PYY; DAD1R; PD; TH; NPS-2143; αSyn; GPCR; VGCC; MPTP; 5-HT; DA; Parkinson’s disease
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2024.116518

The Calcium-sensing receptor (CaSR) participates in the regulation of gastrointestinal (GI) motility under normal conditions and might be involved in the regulation of GI dysmotility in patients with Parkinson's disease (PD). CaSR antagonist-NPS-2143 was applied in in vivo and ex vivo experiments to study the effect and underlying mechanisms of CaSR inhibition on GI dysmotility in the MPTP-induced PD mouse model. Oral intake of NPS-2143 promoted GI motility in PD mice as shown by the increased gastric emptying rate and shortened whole gut transit time together with improved weight and water content in the feces of PD mice, and the lack of influence on normal mice. Meanwhile, the number of cholinergic neurons, the proportion of serotonergic neurons, as well as the levels of acetylcholine and serotonin increased, but the numbers of nitrergic and tyrosine hydroxylase immunoreactive neurons, and the levels of nitric oxide synthase and dopamine decreased in the myenteric plexus in the gastric antrum and colon of PD mice in response to NPS-2143 treatment. Furthermore, the numbers of c-fos positive neurons in the nucleus tractus solitarius (NTS) and cholinergic neurons in the dorsal motor nucleus of the vagus (DMV) increased in NPS-2143 treated PD mice, suggesting the involvement of both the enteric (ENS) and central (CNS) nervous systems. However, ex vivo results showed that NPS-2143 directly inhibited the contractility of antral and colonic strips in PD mice via a non-ENS mediated mechanism. Further studies revealed that NPS-2143 directly inhibited the voltage gated Ca2+ channels, which might, at least in part, explain its direct inhibitory effects on the GI muscle strips. CaSR inhibition by its antagonist ameliorated GI dysmotility in PD mice via coordinated neuronal regulation by both ENS and CNS in vivo, although the direct effects of CaSR inhibition on GI muscle strips were suppressive. [Display omitted] •Oral intake of NPS-2143 promoted gastrointestinal motility.•ENS and CNS are involved in the effects of NPS-2143 in vivo.•Direct effects of NPS-2143 on gastrointestinal strips is suppressive via VGCC.